Enterprise Value

69.07B

Cash

8.71B

Avg Qtr Burn

N/A

Short % of Float

0.37%

Insider Ownership

0.00%

Institutional Own.

9.91%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Dupixent Details
Eosinophilic Esophagitis

Approved

Quarterly sales

Beyfortus™ (Nirsevimab- alip) Details
Respiratory syncytial virus

Approved

Quarterly sales

BLA

Submission

Tolebrutinib Details
Multiple sclerosis, Autoimmune disease

BLA

Submission

ExPEC9V vaccine Details
Invasive Extraintestinal Pathogenic Escherichia Coli Disease

Phase 3

Data readout

Dupixent Details
Chronic spontaneous urticaria

Phase 3

Data readout

Sarclisa® Details
Cancer, Multiple myeloma

Phase 3

Update

Tzield (Teplizumab) Details
Type 1 diabetes, Diabetes

Phase 3

Update

Amlitelimab Details
Atopic dermatitis

Phase 3

Initiation

Frexalimab Details
Autoimmune disease, Multiple sclerosis

Phase 3

Initiation

Ordesekimab (PRV-015) (anti-IL-15) Details
Celiac disease, Immune Disorders

Phase 2b

Data readout

PRV-3279 Details
Systemic lupus erythematosus, Autoimmune disease

Phase 2a

Data readout